ATE218859T1 - Liganden des neuropeptids y - Google Patents

Liganden des neuropeptids y

Info

Publication number: ATE218859T1
Authority: AT; Austria
Prior art keywords: neuropeptide; ligands; formula; agonists; regulators
Prior art date: 1996-08-23

Application number

AT97939524T

Other languages

English (en)

Inventor

Vlad Edward Gregor

Yufeng Hong

Anthony Lai Ling

Eileen Valenzuela Tompkins

Original Assignee

Agouron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-23

Filing date

1997-08-22

Publication date

2002-06-15

1997-08-22 Application filed by Agouron Pharma filed Critical Agouron Pharma

2002-06-15 Application granted granted Critical

2002-06-15 Publication of ATE218859T1 publication Critical patent/ATE218859T1/de

Links

101710151321 Melanostatin Proteins 0.000 title abstract 3
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title abstract 3
239000003446 ligand Substances 0.000 title abstract 2
102100028427 Pro-neuropeptide Y Human genes 0.000 title 1
102400000064 Neuropeptide Y Human genes 0.000 abstract 2
239000000556 agonist Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Other In-Based Heterocyclic Compounds (AREA)

AT97939524T 1996-08-23 1997-08-22 Liganden des neuropeptids y ATE218859T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2579196P	1996-08-23	1996-08-23
PCT/US1997/014854 WO1998007420A1 (en)	1996-08-23	1997-08-22	Neuropeptide-y ligands

Publications (1)

Publication Number	Publication Date
ATE218859T1 true ATE218859T1 (de)	2002-06-15

Family

ID=21828075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97939524T ATE218859T1 (de)	1996-08-23	1997-08-22	Liganden des neuropeptids y

Country Status (11)

Country	Link
US (1)	US6849733B1 (de)
EP (1)	EP0984778B1 (de)
JP (1)	JP2001502296A (de)
AT (1)	ATE218859T1 (de)
AU (1)	AU4159297A (de)
CA (1)	CA2268051A1 (de)
DE (1)	DE69713402T2 (de)
DK (1)	DK0984778T3 (de)
ES (1)	ES2176776T3 (de)
PT (1)	PT984778E (de)
WO (1)	WO1998007420A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9703414D0 (sv) *	1997-09-23	1997-09-23	Astra Ab	New compounds
SE9802207D0 (sv) *	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
SE9802206D0 (sv) *	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
EP1033366A3 (de) *	1999-02-18	2000-12-27	Pfizer Products Inc.	Amid-Derivate mit Neuropeptid Y (NPY) -antagonistischer Wirkung
US6774243B2 (en)	1999-08-24	2004-08-10	Agouron Pharmaceuticals, Inc.	Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
US6355807B1 (en)	1999-08-24	2002-03-12	Agouron Pharmaceuticals, Inc.	Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
DZ3415A1 (fr)	2000-08-31	2002-03-07	Chiron Corp	Guanidinobenzamides comme mc4-r agonistes.
BR0115079A (pt) *	2000-10-30	2003-08-19	Warner Lambert Co	Ligandos do receptor de serotonina à base de amidino-uréia e composições destes, seus usos farmacêuticos e métodos para a suas sìnteses
PT1385823E (pt)	2001-04-09	2007-01-31	Novartis Vaccines & Diagnostic	Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
DE60333937D1 (de)	2002-05-23	2010-10-07	Novartis Vaccines & Diagnostic	Substituierte quinazolinone verbindungen
ATE462432T1 (de)	2003-05-05	2010-04-15	Probiodrug Ag	Glutaminylcyclase-hemmer
KR20060018217A (ko)	2003-05-23	2006-02-28	카이론 코포레이션	Ｍｃ4-ｒ 작용제로서 구아니디노-치환된 퀴나졸리논 화합물
JP2007509898A (ja)	2003-11-03	2007-04-19	プロビオドルグエージー	神経障害治療に有用な組合せ
WO2005051391A1 (en)	2003-11-19	2005-06-09	Chiron Corporation	Quinazolinone compounds with reduced bioaccumulation
KR101099206B1 (ko)	2004-02-05	2011-12-27	프로비오드룩 아게	신규한 글루타미닐 시클라제 저해제
AU2006235200A1 (en) *	2005-04-15	2006-10-19	Regenertech Pty Limited	Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
US7273882B2 (en) *	2005-06-21	2007-09-25	Bristol-Myers Squibb Company	Aminoacetamide acyl guanidines as β-secretase inhibitors
ES2778846T3 (es)	2005-11-08	2020-08-12	Vertex Pharma	Moduladores heterocíclicos de transportadores de casete de unión a ATP
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US7657504B2 (en) *	2006-10-10	2010-02-02	Microsoft Corporation	User interface for displaying images of sights
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (de)	2006-11-30	2012-04-18	Probiodrug AG	Neue inhibitoren von glutaminylcyclase
CA2679446C (en)	2007-03-01	2016-05-17	Probiodrug Ag	New use of glutaminyl cyclase inhibitors
US9656991B2 (en)	2007-04-18	2017-05-23	Probiodrug Ag	Inhibitors of glutaminyl cyclase
CN102863432B (zh)	2007-05-09	2016-09-07	沃泰克斯药物股份有限公司	Cftr调节剂
KR20150063170A (ko)	2007-12-07	2015-06-08	버텍스 파마슈티칼스 인코포레이티드	3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
WO2009076142A2 (en)	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
CN106432213A (zh)	2008-02-28	2017-02-22	沃泰克斯药物股份有限公司	作为cftr调节剂的杂芳基衍生物
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
DK2545047T3 (da)	2010-03-10	2014-07-28	Probiodrug Ag	Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
BR112012026255A2 (pt)	2010-04-07	2017-03-14	Vertex Pharma	composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
EP2560953B1 (de)	2010-04-21	2016-01-06	Probiodrug AG	Hemmer der glutaminylzyklase
WO2012123563A1 (en)	2011-03-16	2012-09-20	Probiodrug Ag	Benz imidazole derivatives as inhibitors of glutaminyl cyclase
DK2806859T3 (da)	2012-01-25	2019-08-05	Vertex Pharma	Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
DK3068392T5 (da)	2013-11-12	2021-09-20	Vertex Pharma	Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
WO2016081556A1 (en)	2014-11-18	2016-05-26	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
JP6792636B2 (ja) *	2016-11-25	2020-11-25	日本曹達株式会社	グアニジン化合物および殺菌剤
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0086774A1 (de) *	1981-08-24	1983-08-31	Rorer International (Overseas) Inc.	Behandlung von kozzidieninfektionen mittels amidinoharnstoff- oder amidinothioharnstoffabkömmlingen
WO1983000624A1 (en) *	1981-08-24	1983-03-03	Chou, Billy, Ja-Ray	Promotion of feed efficiency in animals
US5380945A (en) *	1989-06-21	1995-01-10	Abbott Laboratories	Guanidino compounds as regulators of nitric oxide synthase
DE59006842D1 (de) *	1990-03-30	1994-09-22	Heumann Pharma Gmbh & Co	Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung.
US5583238A (en) *	1990-11-19	1996-12-10	G. D. Searle & Co.	Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5482947A (en) *	1990-11-19	1996-01-09	Talley; John J.	Retroviral protease inhibitors
DE4326465A1 (de) *	1993-01-20	1995-02-09	Thomae Gmbh Dr K	Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4301452A1 (de) *	1993-01-20	1994-07-21	Thomae Gmbh Dr K	Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2701480B1 (fr)	1993-02-15	1995-05-24	Sanofi Elf	Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
EP0895781A3 (de)	1994-10-20	1999-07-07	Eli Lilly And Company	Verwendung von Benzofuranen, Benzothiophene oder Indolen zur Herstellung eines Arzneimittels zur Behandlung von durch einen Überschuss an Tachykininen hergerufenen Störungen
US6562862B1 (en)	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
BR9509610A (pt)	1994-11-07	1997-10-28	Pfizer	Ligandos específicos de neuropeptideo Y1

1997
- 1997-08-22 EP EP97939524A patent/EP0984778B1/de not_active Expired - Lifetime
- 1997-08-22 DK DK97939524T patent/DK0984778T3/da active
- 1997-08-22 ES ES97939524T patent/ES2176776T3/es not_active Expired - Lifetime
- 1997-08-22 PT PT97939524T patent/PT984778E/pt unknown
- 1997-08-22 JP JP10511019A patent/JP2001502296A/ja not_active Ceased
- 1997-08-22 DE DE69713402T patent/DE69713402T2/de not_active Expired - Fee Related
- 1997-08-22 US US08/916,527 patent/US6849733B1/en not_active Expired - Fee Related
- 1997-08-22 WO PCT/US1997/014854 patent/WO1998007420A1/en not_active Ceased
- 1997-08-22 AT AT97939524T patent/ATE218859T1/de not_active IP Right Cessation
- 1997-08-22 CA CA002268051A patent/CA2268051A1/en not_active Abandoned
- 1997-08-22 AU AU41592/97A patent/AU4159297A/en not_active Abandoned

Also Published As

Publication number	Publication date
US6849733B1 (en)	2005-02-01
WO1998007420A1 (en)	1998-02-26
EP0984778A4 (de)	2000-06-07
CA2268051A1 (en)	1998-02-26
DE69713402D1 (de)	2002-07-18
JP2001502296A (ja)	2001-02-20
AU4159297A (en)	1998-03-06
PT984778E (pt)	2002-09-30
DK0984778T3 (da)	2002-09-16
DE69713402T2 (de)	2002-11-07
EP0984778B1 (de)	2002-06-12
ES2176776T3 (es)	2002-12-01
EP0984778A1 (de)	2000-03-15

Legal Events

Date	Code	Title	Description
2002-11-15	UEP	Publication of translation of european patent specification
2007-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69713402D1 (de)	2002-07-18	Liganden des neuropeptids y
UY34152A (es)	2013-02-28	?oxazolidinonas substituidas y su uso?.
SK86699A3 (en)	2000-11-07	Nitrogen containing heteroaromatics as factor xa inhibitors
DK0572166T3 (da)	1997-09-01	Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer
AU1980997A (en)	1997-09-16	Synthetic Multimerizing Agents
TR199901653T2 (xx)	1999-10-21	Fitalazinonlar.
BG104670A (en)	2001-05-31	4-(2-keto-1-benzimidazolinyl)piperidinne compounds as orl1-receptor agonists
BR9808491A (pt)	2000-05-23	Compostos calcilìticos
ATE228111T1 (de)	2002-12-15	M-amidinophenyl-analoga als faktor-xa-inhibitoren
BG103310A (en)	2000-05-31	Benzonaphthyridins as bronchial therapeutical means
IT1269176B (it)	1997-03-21	Eterobicicli ad attivita' fungicida
SE0004245D0 (sv)	2000-11-20	Novel compounds and their use
PL310940A1 (en)	1996-01-08	Organic compounds
TR199903014T2 (xx)	2000-05-22	5-HT1F Agonistleri olarak yararl� karboksamitler.
ATE245642T1 (de)	2003-08-15	Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
NO981393D0 (no)	1998-03-27	Guanidinoproteasehemmere
BG105539A (bg)	2001-12-29	Елетриптан хидробромид монохидрат
GB2324091A (en)	1998-10-14	Metalloproteinase inhibitors
DK1204659T3 (da)	2004-04-05	Serotonerge benzofuraner
RU95106653A (ru)	1996-11-20	Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
PT1377574E (pt)	2005-05-31	6-fenilbenzonaftiridinas
EA199900534A1 (ru)	2000-02-28	Имидазопиридазины
ATE280169T1 (de)	2004-11-15	Serotonerge benzothiophene
TR200100133T2 (tr)	2001-06-21	FKBP İnhibitörleri
ES2103794T3 (es)	1997-10-01	Pirazolinas, pirazolidinas e hidrazinas artropodicidas.